The new Pricing System in Russia will lead to price decreases for many medicines - https://t.co/uOTiv4G5qT

Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement? - https://t.co/fn1yw4QwPb

Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation. - https://t.co/JaMsARTqkd

Prices of Pfizer's leukaemia drug Bosulif cut by 13% in Germany after HTA - https://t.co/Dmwal4RyuX

New set of rules regulating medicine prices in Kazakhstan - https://t.co/6TMLmw7etl

Malaysian authorities approve the introduction of IRP - https://t.co/aZNjtkvNbc

Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices - https://t.co/Tczhkp1sUs

Pricing pharmaceuticals: The transition from prospective qualitative research to predictive data analytics - https://t.co/UIRe7jJgXn

Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective? https://t.co/W8dHEA1tNu

Taking stock:  European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations   https://t.co/Ar1IA9H3ss

Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme https://t.co/zn3nhxrvHU

Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry? https://t.co/6WoHxLdRVR

Thanks for a great Day 1. The GPI team looks forward to doing it all again today! #PPMA @globalpricing

The GPI team looks forward to meeting all delegates at PPMA in London next week (# Stand 31). We are running a short GPI PPMA Challenge Quiz for congress delegates. Go on to the PPMA EU 2018 Congress App for details. #PPMA

What will shape the global pharmaceutical pricing environment in 2018? https://t.co/9vyE96EBgI

Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER

Load More...

The new Pricing System in Russia will lead to price decreases for many medicines - https://t.co/uOTiv4G5qT

Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement? - https://t.co/fn1yw4QwPb

Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation. - https://t.co/JaMsARTqkd

Prices of Pfizer's leukaemia drug Bosulif cut by 13% in Germany after HTA - https://t.co/Dmwal4RyuX

New set of rules regulating medicine prices in Kazakhstan - https://t.co/6TMLmw7etl

Malaysian authorities approve the introduction of IRP - https://t.co/aZNjtkvNbc

Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices - https://t.co/Tczhkp1sUs

Pricing pharmaceuticals: The transition from prospective qualitative research to predictive data analytics - https://t.co/UIRe7jJgXn

Combination therapy for melanoma: What are the current challenges in pricing & access from EU and US payers’ perspective? https://t.co/W8dHEA1tNu

Taking stock:  European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations   https://t.co/Ar1IA9H3ss

Learn – Engage – Apply – Perform! GPI has launched LEAP; our new career development & training programme https://t.co/zn3nhxrvHU

Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry? https://t.co/6WoHxLdRVR

Thanks for a great Day 1. The GPI team looks forward to doing it all again today! #PPMA @globalpricing

The GPI team looks forward to meeting all delegates at PPMA in London next week (# Stand 31). We are running a short GPI PPMA Challenge Quiz for congress delegates. Go on to the PPMA EU 2018 Congress App for details. #PPMA

What will shape the global pharmaceutical pricing environment in 2018? https://t.co/9vyE96EBgI

Spark's planned price for Luxturna gene therapy for rare blindness too high: ICER

Load More...